BCRX•benzinga•
BioCryst Pharmaceuticals Soars 23% In One Session - Here's Why It Surprised Investors
Summary
BioCryst posted $134.2 million in Q1 revenue, raised 2025 Orladeyo guidance, and now expects full-year profitability and positive cash flow.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 5, 2025 by benzinga